Page 2 - Divis Laboratories
Divi's Laboratories surges 6%, hits a record high on strong Q2 numbers
Q2FY21 EBITDA margins expanded 843 bps YoY to 42.4 per cent due to significantly better gross margin performance and lower other expenditure.
 "Divi's Laboratories surges 6%, hits a record high on strong Q2 numbers")
Sensex ends 214 pts higher amid broad-based buying; Asian Paints gains 4%
All that happened in the markets today
 "Sensex ends 214 pts higher amid broad-based buying; Asian Paints gains 4%")
Should you buy Divi's Lab, SBI Life before they enter Nifty50 in September?
Changes have been made in several indices, including Nifty 500, Nifty 200, Nifty 100 and Nifty Midcap 150
 "Should you buy Divi's Lab, SBI Life before they enter Nifty50 in September?")
Divi's Lab hits new high as Chippada unit gets zero USFDA observations
In the past month, Divi's Lab has outperformed the market by surging 10 per cent, as compared to 1.4 per cent decline in the S&P BSE Sensex
 "Divi's Lab hits new high as Chippada unit gets zero USFDA observations")
Top stock recommendations by Anand Rathi: Buy Divis Labs, Godfrey Phillips
Stock calls by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers
 "Top stock recommendations by Anand Rathi: Buy Divis Labs, Godfrey Phillips")
Divi's Laboratories slips 9% on subdued June quarter results
Operational revenue during the quarter grew 17 per cent YoY at Rs 1,163 crore against Rs 995 crore in the corresponding quarter of previous year
 "Divi's Laboratories slips 9% on subdued June quarter results")
Divis Laboratories on strong growth trend, experts expect margins to expand
Strong demand for active ingredients is further accentuated by shortages even as prospects in custom synthesis business remain firm
 "Divis Laboratories on strong growth trend, experts expect margins to expand")
Divis Laboratories' Q3 net profit rises 69% to Rs 379.49 cr; revenue up 30%
Divis Labs had reported a net profit of Rs 397.65 crore on total revenue of Rs 1,365 crore in the quarter ended September 2018
 "Divis Laboratories' Q3 net profit rises 69% to Rs 379.49 cr; revenue up 30%")
Divis Laboratories to spend Rs 15 billion on expansion by next year
The company said it would be investing Rs 6 billion each on its Unit-2 at the Vizag SEZ in Andhra and Unit-1 of its Nalgonda SEZ in Telangana
 "Divis Laboratories to spend Rs 15 billion on expansion by next year")
Divi's Labs gains as USFDA closes out warning letter for Vizag unit
Thus far in the current month, Divi's Labs outperformed the market by gaining 23% after the company on November 2, said that the USFDA will lift import alert for its Visakhapatnam unit.
 "Divi's Labs gains as USFDA closes out warning letter for Vizag unit")
Resolved all issues leading to USFDA import alert on Vizag unit: Divis Labs
BS ReporterHyderabad, 20 September: Hyderabad-based Divis Laboratories Limited on Wednesday said Unit 2 in Visakhapatnam, which has been under import alert for the past six months, has resolved all the previous observations of the US Food and Drug Administration(USFDA) in a latest full cGMP verification conducted by the inspection teamThe successful implementation of post-audit corrective plan as indicated by the company will pave the way for lifting of import alert issued under clause 66-40 related to manufacturing side issues. Responding to the news, the company scrip rose as much as 8.13 percent or by Rs 70 at Rs 934 in the afternoon trade on Bombay Stock Exchange.While clearing the plant level issues related to the previous set of observations, the USFDA team has issued a Form 483 with a set of 6 fresh observation following during its audit conducted from September 11-19. Without giving any specific details, Divis management stated that the new set of observations were of ...
 "Resolved all issues leading to USFDA import alert on Vizag unit: Divis Labs")
USFDA issues warning letter to Divis Labs for Vishakhapatnam unit
Company, however, did not provide details of the warning letter
 "USFDA issues warning letter to Divis Labs for Vishakhapatnam unit")
Divi's Labs tanks over 30% in two trading days; hits 28-month low
The stock was down 14% to Rs 745 in intra-day trade, extending its Friday's 22% fall on the BSE.
 "Divi's Labs tanks over 30% in two trading days; hits 28-month low")
Divi's Lab hits 52-week low; stock tanks 17% intra-day
The stock was down 17% to Rs 918 on the BSE on back of heavy volumes.
 "Divi's Lab hits 52-week low; stock tanks 17% intra-day")
Divi's Vizag unit gets form 483, five observations from USFDA
The company should respond to form 483 in writing with corrective action plan, then implement that expeditiously
Divis Laboratories hits record high on healthy Q1 results
The stock rallied 5.5% to Rs 1,255, also its record high on the BSE.
 "Divis Laboratories hits record high on healthy Q1 results")
Divis Labs Q4 standalone net up 41% to Rs 322 crore
total income from operations up 34% to Rs 1,095 cr; full-year profit up 29% to Rs 1,108 crore
 "Divis Labs Q4 standalone net up 41% to Rs 322 crore")
Divis Lab gains on successful USFDA inspection of its Unit-2 facility at Visakhapatnam
The stock rallied nearly 4% to Rs 1,030 on the BSE in early morning trade.
 "Divis Lab gains on successful USFDA inspection of its Unit-2 facility at Visakhapatnam")
